Stay updated with breaking news from Roger Adsett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Insmed (NASDAQ:INSM – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. A number of other brokerages have also issued reports on INSM. Credit Suisse Group reissued an “outperform” rating and issued a $46.00 target price on shares of […]
Insmed Incorporated (NASDAQ:INSM – Get Rating) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 11,040,000 shares, an increase of 6.0% from the February 28th total of 10,420,000 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover […]
StockNews.com upgraded shares of Insmed (NASDAQ:INSM – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Tuesday. A number of other brokerages also recently weighed in on INSM. The Goldman Sachs Group lowered their target price on shares of Insmed from $44.00 to $39.00 and set […]
Insmed Inc. promoted Drayton Wise to chief commercial officer, the Bridgewater-based biopharmaceutical company announced May 23.
Brokerages expect that Insmed Incorporated (NASDAQ:INSM – Get Rating) will post earnings of ($0.92) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Insmed’s earnings, with estimates ranging from ($0.98) to ($0.77). Insmed reported earnings per share of ($0.89) during the same quarter last year, which suggests a […]